Cancelled meetings and assessment delays: HTA bodies are revising priorities in response to COVID-19

By Nicola Allen, Associate Director Email: nallen@partners4access.com The priorities of health technology assessment (HTA) bodies are evolving as health care systems around the world are seeking to manage the strain of the Covid-19 pandemic and the biopharmaceutical industry are rising to the challenge to find an effective treatment. Initially, agencies moved in-person meetings to teleconferences…

Deadline day approaches for Israel’s market entry hopefuls

By Erfan Akbraian, Analyst Email: eakbraian@partners4access.com Majority of orphan drug manufacturers do not currently view Israel as an early launch opportunity. However, universal reimbursed access to high quality healthcare which is at par with Western European countries, combined with the expansion of the prenatal and new-born screening programmes[1] that have considerably improved diagnosis rates is…

Evolution of payment models for cell and gene therapies in Italy

By Joanna Fernandes, Associate Consultant Email: jfernandes@partners4access.com Cell and gene therapies (CGTs) are considered one-time transformative treatments, positioned as having life-long benefits. These new therapies are challenging the traditional business model, with health technology assessment (HTA) and reimbursement processes having been established around chronic therapies. This has led to one of the biggest hurdles currently…

P4A sponsors World Orphan Drug Congress Europe 2019

Leading specialist market access consultancy Partners4Access has announced their gold sponsorship of the biotech industry conference World Orphan Drug Congress (WODC) Europe. The event will take place at Hotel Sofia, Barcelona between November 13-14, 2019. P4A’s Sophie Schmitz, managing partner; Akshay Kumar, partner; Aparna Krishnan, director and Nicola Allen, associate director will be attending the…

Orphan Drugs in Colombia: Practical Limitations to Access

By Ciaran Cassidy, Analyst Email: ccassidy@partners4access.com Colombia, like much of Latin America, is receiving attention from the pharmaceutical industry as an emerging market (1). Through the introduction of a universal healthcare system, it seems to provide an attractive opportunity for manufacturers. In this article we will review the Colombian healthcare system from an orphan drugs…

Scaling the healthcare wall: is Mexico an attractive market for high cost drug makers?

By Jack Rawson, Analyst Email: jrawson@partners4access.com At first glance Mexico presents a significant opportunity for drug manufacturers, with a large population of over 126 million, a developing economy and universal access to reimbursed healthcare. The aging population is also placing an increased need for healthcare services and statistics on the demand for drugs are favourable.…